Show simple item record

dc.contributor.authorAmir, Eitan
dc.contributor.authorHughes, Sarah
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorThatcher, Nick
dc.contributor.authorOstoros, Gyula
dc.contributor.authorTimar, Jozsef
dc.contributor.authorTovari, Jozsef
dc.contributor.authorKovacs, Gabor
dc.contributor.authorDome, Balazs
dc.date.accessioned2009-04-02T16:03:14Z
dc.date.available2009-04-02T16:03:14Z
dc.date.issued2008-08
dc.identifier.citationTargeting blood vessels for the treatment of non-small cell lung cancer. 2008, 8 (5):392-403 Curr Cancer Drug Targetsen
dc.identifier.issn1873-5576
dc.identifier.pmid18690845
dc.identifier.urihttp://hdl.handle.net/10541/59156
dc.description.abstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Although modest survival benefit has been observed with surgery, radiotherapy and platinum-based chemotherapy, an efficacy plateau has been reached. It has become obvious, therefore, that additional treatments are needed in order to provide an improved survival benefit for these patients. The use of molecular targeted therapies, particularly those against tumor capillaries, has the potential to improve outcomes for NSCLC patients. Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is the first targeted drug that has shown survival advantage when combined with chemotherapy in NSCLC. Other antivascular agents, including vascular disrupting agents (VDAs) and different small-molecule receptor tyrosine kinase inhibitors, have also shown promise in phase I and II trials in NSCLC. The aim of this study is to describe the clinical properties of these drugs and to discuss the evidence that supports their use in the treatment of NSCLC. Furthermore, we plan to review the main pitfalls of antivascular strategies in NSCLC cancer therapy as well as assess the future direction of these treatment methods with an emphasis on clarifying the molecular background of the effects of these drugs and defining the biomarkers.
dc.language.isoenen
dc.subjectNon-Small-Cell Lung Canceren
dc.subjectLung Canceren
dc.subjectBlood Vesselsen
dc.subjectRadiotherapyen
dc.subjectPlatinum-Based Chemotherapyen
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAnimals
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshClinical Trials as Topic
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshNeovascularization, Pathologic
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshVascular Endothelial Growth Factor A
dc.titleTargeting blood vessels for the treatment of non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.en
dc.identifier.journalCurrent Cancer Drug Targetsen
html.description.abstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Although modest survival benefit has been observed with surgery, radiotherapy and platinum-based chemotherapy, an efficacy plateau has been reached. It has become obvious, therefore, that additional treatments are needed in order to provide an improved survival benefit for these patients. The use of molecular targeted therapies, particularly those against tumor capillaries, has the potential to improve outcomes for NSCLC patients. Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is the first targeted drug that has shown survival advantage when combined with chemotherapy in NSCLC. Other antivascular agents, including vascular disrupting agents (VDAs) and different small-molecule receptor tyrosine kinase inhibitors, have also shown promise in phase I and II trials in NSCLC. The aim of this study is to describe the clinical properties of these drugs and to discuss the evidence that supports their use in the treatment of NSCLC. Furthermore, we plan to review the main pitfalls of antivascular strategies in NSCLC cancer therapy as well as assess the future direction of these treatment methods with an emphasis on clarifying the molecular background of the effects of these drugs and defining the biomarkers.


This item appears in the following Collection(s)

Show simple item record